- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced (unresectable and/or metastatic) leiomyosarcoma
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1598KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 413KB)
Trabectedin – July 2021
Trabectedin: Powder for I.V. infusion 0.25 mg, Powder for I.V. infusion 1 mg; Yondelis®
Last updated
29 October 2021